7 employees
Verseau focus is building a pipeline of first-in-class therapies that modulate macrophages to trigger a coordinated immune attack on cancer.
2017
$50M
from 2 investors over 2 rounds
Verseau Therapeutics raised $50M on October 21, 2019
Investors: 20/20 HealthCare Partners and 上海涌铧投资管理有限公司